Skip to main content
. 2017 Jul 3;3:24. doi: 10.1038/s41523-017-0028-4

Table 1.

Clinical characteristics of patients enrolled on the BRE09-146 clinical trial

BRE09-146 Arm A cisplatin (n = 65) Arm B cisplatin + rucaparib (n = 70) Subjects from arm B for this study (n = 38)
Median age 48 (27–69) 47 (21–75) 47 (21–66)
Race
a. African American 20.0% 18.6% 13.2%
b. White 75.4% 72.9% 73.7%
c. Asian 1.5% 4.3% 7.9%
d. Others 3.1% 4.3% 5.3%
Neoadjuvant chemotherapy
a. Anthracycline 89.2% 88.6% 92.1%
b. Cyclophosphamide 95.4% 90.0% 92.1%
c. Taxane 95.4% 92.9% 92.1%
d. Carboplatin 1.5% 10.0% 10.5%
e. Unknown 3.1% 2.9% 0%
Radiation therapy 87.7% 85.7% 84.2%
Median residual lymph node positivity (LN+) 1 (0–15) 1 (0–38) 1 (0–38)
Median residual cancer burden 2.6 (0–5.0) 2.7 (0–5.3) 3.1 (0–5.3)